Therapeutic Strategy Details
| Strategy ID: | S11 |
| Strategy: | digital therapeutics |
| Other Terms: | Percutaneous left atrial appendage occlusion (LAAO); Antiplatelet therapy; inhibition of PAPP-A; gut microbiota modulation; innovative absorption-based approach; application of the effective antimicrobial agents against Aeromonas under the supervision of infectious doctors; percutaneous catheter-directed treatment approach; application of adequate drug policy measures; appropriate antibiotics; Digital therapeutics; digitalis; preventing inappropriate ESA use |
| Related Targets: | C3; CD20 |
| Related Drugs: | oral anticoagulation; antiplatelet therapy; a monoclonal antibody that blocks the proteolytic activity of PAPP-A against IGFBP4; synbiotic; cephalosporins; thrombolytics; rosuvastatin; warfarin; ""appropriate antibiotics""; ""high-dose steroid therapy""; antimetabolics; anti-CD20; antiarrhythmic agents; digitalis; direct oral anticoagulants; antidepressants; Erythropoiesis-stimulating agents; originator ESA; biosimilars |
| Mechanism: | |
| Reference (PMIDs): | 31715006; 31990681; 32164382; 32382057; 32432829; 32545989; 32567542; 32877497; 32877820; 33067914 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria |
|---|
| Article ID | PMID | Source | Title |
|---|